NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|186526663|ref|NP_001119311|]
View 

ENHANCED DISEASE RESISTANCE protein (DUF1336) [Arabidopsis thaliana]

Protein Classification

START domain-containing protein; SRPBCC family protein( domain architecture ID 13321788)

START (steroidogenic acute regulatory protein (StAR)-related lipid transfer) domain-containing protein may bind lipids| SRPBCC (START/RHOalphaC/PITP/Bet v1/CoxG/CalC) family protein may have a deep hydrophobic ligand-binding pocket

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
START cd00177
Lipid-binding START domain of mammalian STARD1-STARD15 and related proteins; This family ...
238-437 1.10e-36

Lipid-binding START domain of mammalian STARD1-STARD15 and related proteins; This family includes the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domains of mammalian STARD1-STARD15, and related domains, such as the START domain of the Arabidopsis homeobox protein GLABRA 2. The mammalian STARDs are grouped into 8 subfamilies. This family belongs to the SRPBCC (START/RHO_alpha_C/PITP/Bet_v1/CoxG/CalC) domain superfamily of proteins that bind hydrophobic ligands. SRPBCC domains have a deep hydrophobic ligand-binding pocket. For some members of this family, specific lipids that bind in this pocket are known; these include cholesterol (STARD1/STARD3/ STARD4/STARD5), 25-hydroxycholesterol (STARD5), phosphatidylcholine (STARD2/ STARD7/STARD10), phosphatidylethanolamine (STARD10) and ceramides (STARD11). The START domain is found either alone or in association with other domains. Mammalian STARDs participate in the control of various cellular processes including lipid trafficking between intracellular compartments, lipid metabolism, and modulation of signaling events. Mutation or altered expression of STARDs is linked to diseases such as cancer, genetic disorders, and autoimmune disease. The Arabidopsis homeobox protein GLABRA 2 suppresses root hair formation in hairless epidermal root cells.


:

Pssm-ID: 176851 [Multi-domain]  Cd Length: 193  Bit Score: 135.16  E-value: 1.10e-36
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 238 DNGDAIEAHE-WKCVRTINGVRIFEDVanFKAGRGVLVKAVAVVEASADTVFEVLLNIDKhqRYEWDAVTGDSEKIDSYE 316
Cdd:cd00177    6 ELLELLEEPEgWKLVKEKDGVKIYTKP--YEDSGLKLLKAEGVIPASPEQVFELLMDIDL--RKKWDKNFEEFEVIEEID 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 317 GHYDVIYCIYDPKYLsrwQSKRDFVFSRQWVRGQDGTYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLkkrsdaETP 396
Cdd:cd00177   82 EHTDIIYYKTKPPWP---VSPRDFVYLRRRRKLDDGTYVIVSKSVDHDSHPKEKGYVRAEIKLSGWIIEPL------DPG 152
                        170       180       190       200
                 ....*....|....*....|....*....|....*....|.
gi 186526663 397 SCLVTHMLEIHSKRWCKWKRTSYSKFEKTIPYALLLQVAGL 437
Cdd:cd00177  153 KTKVTYVLQVDPKGSIPKSLVNSAAKKQLASFLKDLRKAKK 193
PLN00188 super family cl33420
enhanced disease resistance protein (EDR2); Provisional
60-585 2.27e-34

enhanced disease resistance protein (EDR2); Provisional


The actual alignment was detected with superfamily member PLN00188:

Pssm-ID: 215094 [Multi-domain]  Cd Length: 719  Bit Score: 138.79  E-value: 2.27e-34
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663  60 YFGWVYHLGVNKIGHEYCNLRFLFIRGKYVEMYKRDPHENpdIKPIRRGVIGPTMVIEELGRrKVNHGD-VYVIRFYNRL 138
Cdd:PLN00188   6 YEGWMVRYGRRKIGRSYIHMRYFVLESRLLAYYKKKPQDN--QVPIKTLLIDGNCRVEDRGL-KTHHGHmVYVLSVYNKK 82
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 139 DESRKGEIACATAGEALKWVEAFEEA-KQQAEYALSRG---GSTRTKLSMEANI----------------DLEGHRPRVR 198
Cdd:PLN00188  83 EKYHRITMAAFNIQEALIWKEKIESViDQHQDSQVPNGnkyASFEYKSGMDNGRtasssdhesqfsaqedEEDTHRDLLR 162
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 199 RYAyglkklirIGQG-PESLLrqSSTLVNDVrgdGFYEGGDNGDAIEAHEWKCVRTINGVRIFEDVANF-----KAGRGV 272
Cdd:PLN00188 163 RTT--------IGNGpPDSVL--DWTKEFDS---ELSNQNSNNQAFSRKHWRLLQCQNGLRIFEELLEVdylprSCSRAM 229
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 273 lvKAVAVVEASADTVFEVLLNIDKhQRYEWDAVTGDSEKIDSYEGHYDVIYCIYDPKYLSRWQSKRDFVFSRQWVRGQDG 352
Cdd:PLN00188 230 --KAVGVVEATCEEIFELVMSMDG-TRFEWDCSFQYGSLVEEVDGHTAILYHRLQLDWFPMFVWPRDLCYVRYWRRNDDG 306
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 353 TYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLKKRSdaETPSCLVTHMLEIHSKRWCKWKRTSYSkfektipYALLL 432
Cdd:PLN00188 307 SYVVLFRSREHENCGPQPGFVRAHLESGGFNISPLKPRN--GRPRTQVQHLMQIDLKGWGVGYIPSFQ-------QHCLL 377
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 433 Q----VAGLKEYIGAN---------PAFKYETSATVVQSKfqdvpngeyvdeEMEEQFYDATDSSSGEEDEEESDDDDEN 499
Cdd:PLN00188 378 QmlnsVAGLREWFSQTdergappriPVMVNMASASVSSKK------------NQKPQESSPSLDQTNAASRNSVMMDEDS 445
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 500 QDNKEIKVKLKNVSWAIASLSLKRpkapgaSNVLDASVDPvsIDPSQFQGSLRKGNGDKDSNCWNSPSGMGFMIRGKTYL 579
Cdd:PLN00188 446 DDDEEFQIPESEQEPETTKNETKD------TAMEEEPQDK--IDLSCFSGNLRRDDRDKARDCWRISDGNNFKVRSKNFC 517

                 ....*.
gi 186526663 580 KDNAKV 585
Cdd:PLN00188 518 YDKSKI 523
 
Name Accession Description Interval E-value
START cd00177
Lipid-binding START domain of mammalian STARD1-STARD15 and related proteins; This family ...
238-437 1.10e-36

Lipid-binding START domain of mammalian STARD1-STARD15 and related proteins; This family includes the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domains of mammalian STARD1-STARD15, and related domains, such as the START domain of the Arabidopsis homeobox protein GLABRA 2. The mammalian STARDs are grouped into 8 subfamilies. This family belongs to the SRPBCC (START/RHO_alpha_C/PITP/Bet_v1/CoxG/CalC) domain superfamily of proteins that bind hydrophobic ligands. SRPBCC domains have a deep hydrophobic ligand-binding pocket. For some members of this family, specific lipids that bind in this pocket are known; these include cholesterol (STARD1/STARD3/ STARD4/STARD5), 25-hydroxycholesterol (STARD5), phosphatidylcholine (STARD2/ STARD7/STARD10), phosphatidylethanolamine (STARD10) and ceramides (STARD11). The START domain is found either alone or in association with other domains. Mammalian STARDs participate in the control of various cellular processes including lipid trafficking between intracellular compartments, lipid metabolism, and modulation of signaling events. Mutation or altered expression of STARDs is linked to diseases such as cancer, genetic disorders, and autoimmune disease. The Arabidopsis homeobox protein GLABRA 2 suppresses root hair formation in hairless epidermal root cells.


Pssm-ID: 176851 [Multi-domain]  Cd Length: 193  Bit Score: 135.16  E-value: 1.10e-36
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 238 DNGDAIEAHE-WKCVRTINGVRIFEDVanFKAGRGVLVKAVAVVEASADTVFEVLLNIDKhqRYEWDAVTGDSEKIDSYE 316
Cdd:cd00177    6 ELLELLEEPEgWKLVKEKDGVKIYTKP--YEDSGLKLLKAEGVIPASPEQVFELLMDIDL--RKKWDKNFEEFEVIEEID 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 317 GHYDVIYCIYDPKYLsrwQSKRDFVFSRQWVRGQDGTYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLkkrsdaETP 396
Cdd:cd00177   82 EHTDIIYYKTKPPWP---VSPRDFVYLRRRRKLDDGTYVIVSKSVDHDSHPKEKGYVRAEIKLSGWIIEPL------DPG 152
                        170       180       190       200
                 ....*....|....*....|....*....|....*....|.
gi 186526663 397 SCLVTHMLEIHSKRWCKWKRTSYSKFEKTIPYALLLQVAGL 437
Cdd:cd00177  153 KTKVTYVLQVDPKGSIPKSLVNSAAKKQLASFLKDLRKAKK 193
PLN00188 PLN00188
enhanced disease resistance protein (EDR2); Provisional
60-585 2.27e-34

enhanced disease resistance protein (EDR2); Provisional


Pssm-ID: 215094 [Multi-domain]  Cd Length: 719  Bit Score: 138.79  E-value: 2.27e-34
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663  60 YFGWVYHLGVNKIGHEYCNLRFLFIRGKYVEMYKRDPHENpdIKPIRRGVIGPTMVIEELGRrKVNHGD-VYVIRFYNRL 138
Cdd:PLN00188   6 YEGWMVRYGRRKIGRSYIHMRYFVLESRLLAYYKKKPQDN--QVPIKTLLIDGNCRVEDRGL-KTHHGHmVYVLSVYNKK 82
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 139 DESRKGEIACATAGEALKWVEAFEEA-KQQAEYALSRG---GSTRTKLSMEANI----------------DLEGHRPRVR 198
Cdd:PLN00188  83 EKYHRITMAAFNIQEALIWKEKIESViDQHQDSQVPNGnkyASFEYKSGMDNGRtasssdhesqfsaqedEEDTHRDLLR 162
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 199 RYAyglkklirIGQG-PESLLrqSSTLVNDVrgdGFYEGGDNGDAIEAHEWKCVRTINGVRIFEDVANF-----KAGRGV 272
Cdd:PLN00188 163 RTT--------IGNGpPDSVL--DWTKEFDS---ELSNQNSNNQAFSRKHWRLLQCQNGLRIFEELLEVdylprSCSRAM 229
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 273 lvKAVAVVEASADTVFEVLLNIDKhQRYEWDAVTGDSEKIDSYEGHYDVIYCIYDPKYLSRWQSKRDFVFSRQWVRGQDG 352
Cdd:PLN00188 230 --KAVGVVEATCEEIFELVMSMDG-TRFEWDCSFQYGSLVEEVDGHTAILYHRLQLDWFPMFVWPRDLCYVRYWRRNDDG 306
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 353 TYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLKKRSdaETPSCLVTHMLEIHSKRWCKWKRTSYSkfektipYALLL 432
Cdd:PLN00188 307 SYVVLFRSREHENCGPQPGFVRAHLESGGFNISPLKPRN--GRPRTQVQHLMQIDLKGWGVGYIPSFQ-------QHCLL 377
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 433 Q----VAGLKEYIGAN---------PAFKYETSATVVQSKfqdvpngeyvdeEMEEQFYDATDSSSGEEDEEESDDDDEN 499
Cdd:PLN00188 378 QmlnsVAGLREWFSQTdergappriPVMVNMASASVSSKK------------NQKPQESSPSLDQTNAASRNSVMMDEDS 445
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 500 QDNKEIKVKLKNVSWAIASLSLKRpkapgaSNVLDASVDPvsIDPSQFQGSLRKGNGDKDSNCWNSPSGMGFMIRGKTYL 579
Cdd:PLN00188 446 DDDEEFQIPESEQEPETTKNETKD------TAMEEEPQDK--IDLSCFSGNLRRDDRDKARDCWRISDGNNFKVRSKNFC 517

                 ....*.
gi 186526663 580 KDNAKV 585
Cdd:PLN00188 518 YDKSKI 523
START smart00234
in StAR and phosphatidylcholine transfer protein; putative lipid-binding domain in StAR and ...
274-411 9.24e-09

in StAR and phosphatidylcholine transfer protein; putative lipid-binding domain in StAR and phosphatidylcholine transfer protein


Pssm-ID: 214575  Cd Length: 205  Bit Score: 55.90  E-value: 9.24e-09
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663   274 VKAVAVVEASADTVFEVLLNiDKHQRYEWDAVTGDSEKIDSYEGHYDVIYciydpkylsrWQSK--------RDFVFSRQ 345
Cdd:smart00234  46 FRLVGVVPMVCADLVEELMD-DLEYRPEWDKNVAKAETLEVIDNGTVIYH----------YVSKfaagpvspRDFVFVRY 114
                           90       100       110       120       130       140
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 186526663   346 WVRGQDGTYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLKKRsdaetpSCLVTHMLEIHSKRW 411
Cdd:smart00234 115 WREDEDGSYAVVDVSVTHPTSPPESGYVRAENLPSGLLIEPLGNG------PSKVTWVSHADLKGW 174
START pfam01852
START domain;
263-411 7.79e-06

START domain;


Pssm-ID: 426476  Cd Length: 205  Bit Score: 47.01  E-value: 7.79e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663  263 VANFKAGRGVLVKAVAVVEASADTVFEVLLNiDKHQRYEWDAVTGDS---EKIDSyeghyDVIYCIYDPKYLSRWQ-SKR 338
Cdd:pfam01852  34 LQIVEPDHGEASRASGVVPMVAALLVAELLK-DMEYRAQWDKDVRSAetlEVISS-----GGDLQYYVAALVAPSPlSPR 107
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 186526663  339 DFVFSRQWVRGQDGTYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLKKrsdaetPSCLVTHMLEIHSKRW 411
Cdd:pfam01852 108 DFVFLRYWRRLGGGVYVIVDRSVTHPQFPPSSGYVRAERLPSGYLIQPCGN------GPSKVTWVSHADLKGW 174
EDR2_C pfam07059
Protein ENHANCED DISEASE RESISTANCE 2, C-terminal; This family represents the C-terminus ...
563-586 2.25e-04

Protein ENHANCED DISEASE RESISTANCE 2, C-terminal; This family represents the C-terminus (approximately 250 residues) of protein ENHANCED DISEASE RESISTANCE 2 (EDR2) from plants. EDR2 is a negative regulator of the salicylic acid (SA)-mediated resistance to pathogens, including the biotrophic powdery mildew pathogens Golovinomyces cichoracearum and Blumeria graminis, and the downy mildew pathogen Hyaloperonospora parasitica, probably by limiting the initiation of cell death and the establishment of the hypersensitive response (HR).


Pssm-ID: 462076  Cd Length: 211  Bit Score: 42.59  E-value: 2.25e-04
                          10        20
                  ....*....|....*....|....
gi 186526663  563 WNSPSGMGFMIRGKTYLKDNAKVA 586
Cdd:pfam07059   1 WSEPDGSTFKVRGPNYLKDKKKVP 24
 
Name Accession Description Interval E-value
START cd00177
Lipid-binding START domain of mammalian STARD1-STARD15 and related proteins; This family ...
238-437 1.10e-36

Lipid-binding START domain of mammalian STARD1-STARD15 and related proteins; This family includes the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domains of mammalian STARD1-STARD15, and related domains, such as the START domain of the Arabidopsis homeobox protein GLABRA 2. The mammalian STARDs are grouped into 8 subfamilies. This family belongs to the SRPBCC (START/RHO_alpha_C/PITP/Bet_v1/CoxG/CalC) domain superfamily of proteins that bind hydrophobic ligands. SRPBCC domains have a deep hydrophobic ligand-binding pocket. For some members of this family, specific lipids that bind in this pocket are known; these include cholesterol (STARD1/STARD3/ STARD4/STARD5), 25-hydroxycholesterol (STARD5), phosphatidylcholine (STARD2/ STARD7/STARD10), phosphatidylethanolamine (STARD10) and ceramides (STARD11). The START domain is found either alone or in association with other domains. Mammalian STARDs participate in the control of various cellular processes including lipid trafficking between intracellular compartments, lipid metabolism, and modulation of signaling events. Mutation or altered expression of STARDs is linked to diseases such as cancer, genetic disorders, and autoimmune disease. The Arabidopsis homeobox protein GLABRA 2 suppresses root hair formation in hairless epidermal root cells.


Pssm-ID: 176851 [Multi-domain]  Cd Length: 193  Bit Score: 135.16  E-value: 1.10e-36
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 238 DNGDAIEAHE-WKCVRTINGVRIFEDVanFKAGRGVLVKAVAVVEASADTVFEVLLNIDKhqRYEWDAVTGDSEKIDSYE 316
Cdd:cd00177    6 ELLELLEEPEgWKLVKEKDGVKIYTKP--YEDSGLKLLKAEGVIPASPEQVFELLMDIDL--RKKWDKNFEEFEVIEEID 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 317 GHYDVIYCIYDPKYLsrwQSKRDFVFSRQWVRGQDGTYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLkkrsdaETP 396
Cdd:cd00177   82 EHTDIIYYKTKPPWP---VSPRDFVYLRRRRKLDDGTYVIVSKSVDHDSHPKEKGYVRAEIKLSGWIIEPL------DPG 152
                        170       180       190       200
                 ....*....|....*....|....*....|....*....|.
gi 186526663 397 SCLVTHMLEIHSKRWCKWKRTSYSKFEKTIPYALLLQVAGL 437
Cdd:cd00177  153 KTKVTYVLQVDPKGSIPKSLVNSAAKKQLASFLKDLRKAKK 193
PLN00188 PLN00188
enhanced disease resistance protein (EDR2); Provisional
60-585 2.27e-34

enhanced disease resistance protein (EDR2); Provisional


Pssm-ID: 215094 [Multi-domain]  Cd Length: 719  Bit Score: 138.79  E-value: 2.27e-34
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663  60 YFGWVYHLGVNKIGHEYCNLRFLFIRGKYVEMYKRDPHENpdIKPIRRGVIGPTMVIEELGRrKVNHGD-VYVIRFYNRL 138
Cdd:PLN00188   6 YEGWMVRYGRRKIGRSYIHMRYFVLESRLLAYYKKKPQDN--QVPIKTLLIDGNCRVEDRGL-KTHHGHmVYVLSVYNKK 82
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 139 DESRKGEIACATAGEALKWVEAFEEA-KQQAEYALSRG---GSTRTKLSMEANI----------------DLEGHRPRVR 198
Cdd:PLN00188  83 EKYHRITMAAFNIQEALIWKEKIESViDQHQDSQVPNGnkyASFEYKSGMDNGRtasssdhesqfsaqedEEDTHRDLLR 162
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 199 RYAyglkklirIGQG-PESLLrqSSTLVNDVrgdGFYEGGDNGDAIEAHEWKCVRTINGVRIFEDVANF-----KAGRGV 272
Cdd:PLN00188 163 RTT--------IGNGpPDSVL--DWTKEFDS---ELSNQNSNNQAFSRKHWRLLQCQNGLRIFEELLEVdylprSCSRAM 229
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 273 lvKAVAVVEASADTVFEVLLNIDKhQRYEWDAVTGDSEKIDSYEGHYDVIYCIYDPKYLSRWQSKRDFVFSRQWVRGQDG 352
Cdd:PLN00188 230 --KAVGVVEATCEEIFELVMSMDG-TRFEWDCSFQYGSLVEEVDGHTAILYHRLQLDWFPMFVWPRDLCYVRYWRRNDDG 306
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 353 TYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLKKRSdaETPSCLVTHMLEIHSKRWCKWKRTSYSkfektipYALLL 432
Cdd:PLN00188 307 SYVVLFRSREHENCGPQPGFVRAHLESGGFNISPLKPRN--GRPRTQVQHLMQIDLKGWGVGYIPSFQ-------QHCLL 377
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 433 Q----VAGLKEYIGAN---------PAFKYETSATVVQSKfqdvpngeyvdeEMEEQFYDATDSSSGEEDEEESDDDDEN 499
Cdd:PLN00188 378 QmlnsVAGLREWFSQTdergappriPVMVNMASASVSSKK------------NQKPQESSPSLDQTNAASRNSVMMDEDS 445
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 500 QDNKEIKVKLKNVSWAIASLSLKRpkapgaSNVLDASVDPvsIDPSQFQGSLRKGNGDKDSNCWNSPSGMGFMIRGKTYL 579
Cdd:PLN00188 446 DDDEEFQIPESEQEPETTKNETKD------TAMEEEPQDK--IDLSCFSGNLRRDDRDKARDCWRISDGNNFKVRSKNFC 517

                 ....*.
gi 186526663 580 KDNAKV 585
Cdd:PLN00188 518 YDKSKI 523
START smart00234
in StAR and phosphatidylcholine transfer protein; putative lipid-binding domain in StAR and ...
274-411 9.24e-09

in StAR and phosphatidylcholine transfer protein; putative lipid-binding domain in StAR and phosphatidylcholine transfer protein


Pssm-ID: 214575  Cd Length: 205  Bit Score: 55.90  E-value: 9.24e-09
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663   274 VKAVAVVEASADTVFEVLLNiDKHQRYEWDAVTGDSEKIDSYEGHYDVIYciydpkylsrWQSK--------RDFVFSRQ 345
Cdd:smart00234  46 FRLVGVVPMVCADLVEELMD-DLEYRPEWDKNVAKAETLEVIDNGTVIYH----------YVSKfaagpvspRDFVFVRY 114
                           90       100       110       120       130       140
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 186526663   346 WVRGQDGTYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLKKRsdaetpSCLVTHMLEIHSKRW 411
Cdd:smart00234 115 WREDEDGSYAVVDVSVTHPTSPPESGYVRAENLPSGLLIEPLGNG------PSKVTWVSHADLKGW 174
START pfam01852
START domain;
263-411 7.79e-06

START domain;


Pssm-ID: 426476  Cd Length: 205  Bit Score: 47.01  E-value: 7.79e-06
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663  263 VANFKAGRGVLVKAVAVVEASADTVFEVLLNiDKHQRYEWDAVTGDS---EKIDSyeghyDVIYCIYDPKYLSRWQ-SKR 338
Cdd:pfam01852  34 LQIVEPDHGEASRASGVVPMVAALLVAELLK-DMEYRAQWDKDVRSAetlEVISS-----GGDLQYYVAALVAPSPlSPR 107
                          90       100       110       120       130       140       150
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 186526663  339 DFVFSRQWVRGQDGTYTILQFPAVHKKRPAKSGYRRTEITPSTWEIKSLKKrsdaetPSCLVTHMLEIHSKRW 411
Cdd:pfam01852 108 DFVFLRYWRRLGGGVYVIVDRSVTHPQFPPSSGYVRAERLPSGYLIQPCGN------GPSKVTWVSHADLKGW 174
START_1 cd08876
Uncharacterized subgroup of the steroidogenic acute regulatory protein (StAR)-related lipid ...
247-374 3.80e-05

Uncharacterized subgroup of the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain family; Functionally uncharacterized subgroup of the START domain family. The START domain family belongs to the SRPBCC (START/RHO_alpha_C/PITP/Bet_v1/CoxG/CalC) domain superfamily of proteins that bind hydrophobic ligands. SRPBCC domains have a deep hydrophobic ligand-binding pocket. For some mammalian members of the START family (STARDs), it is known which lipids bind in this pocket; these include cholesterol (STARD1, -3, -4, and -5), 25-hydroxycholesterol (STARD5), phosphatidylcholine (STARD2, -7, and -10), phosphatidylethanolamine (STARD10) and ceramides (STARD11). Mammalian STARDs participate in the control of various cellular processes, including lipid trafficking between intracellular compartments, lipid metabolism, and modulation of signaling events. Mutation or altered expression of STARDs is linked to diseases such as cancer, genetic disorders, and autoimmune disease.


Pssm-ID: 176885  Cd Length: 195  Bit Score: 44.95  E-value: 3.80e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 247 EWKCVRTINGVRIFE-DVANFKAgrgVLVKAVAVVEASADTVFEVLLNIDKHQryEWDAVTGDSEKIDSYEGHYDVIYCI 325
Cdd:cd08876   18 DWQLVKDKDGIKVYTrDVEGSPL---KEFKAVAEVDASIEAFLALLRDTESYP--QWMPNCKESRVLKRTDDNERSVYTV 92
                         90       100       110       120       130
                 ....*....|....*....|....*....|....*....|....*....|.
gi 186526663 326 YDPKylsrWQ-SKRDFVF-SRQWVRGQDGTYTIlQFPAVHKKRPAKSGYRR 374
Cdd:cd08876   93 IDLP----WPvKDRDMVLrSTTEQDADDGSVTI-TLEAAPEALPEQKGYVR 138
START_STARD10-like cd08871
Lipid-binding START domain of mammalian STARD10 and related proteins; This subfamily includes ...
273-374 1.07e-04

Lipid-binding START domain of mammalian STARD10 and related proteins; This subfamily includes the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domains of mammalian STARD10 (also known as CGI-52, PTCP-like, and SDCCAG28). The START domain family belongs to the SRPBCC (START/RHO_alpha_C/PITP/Bet_v1/CoxG/CalC) domain superfamily of proteins that bind hydrophobic ligands. SRPBCC domains have a deep hydrophobic ligand-binding pocket. STARD10 binds phophatidylcholine and phosphatidylethanolamine. This protein is widely expressed and is synthesized constitutively in many organs. It may function in the liver in the export of phospholipids into bile. It is concentrated in the sperm flagellum, and may play a role in energy metabolism. In the mammary gland it may participate in the enrichment of lipids in milk, and be a potential marker of differentiation. Its expression is induced in this gland during gestation and lactation. It is overexpressed in mammary tumors from Neu/ErbB2 transgenic mice, in several breast carcinoma cell lines, and in 35% of primary human breast cancers, and may cooperate with c-erbB receptor signaling in breast oncogenesis. It is a potential marker of disease outcome in breast cancer; loss of STARD10 expression in breast cancer strongly predicts an aggressive disease course. The lipid transfer activity of STRAD10 is downregulated by phosphorylation of its Ser284 by CK2 (casein kinase 2).


Pssm-ID: 176880  Cd Length: 222  Bit Score: 43.78  E-value: 1.07e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 186526663 273 LVKAVAV-VEASADTVFEVLLNIDkhQRYEWDAVTGDSEKIDSYEGHYDVIY----CiydPKYLSrwqsKRDFVFSRQWv 347
Cdd:cd08871   48 MIKVSAIfPDVPAETLYDVLHDPE--YRKTWDSNMIESFDICQLNPNNDIGYysakC---PKPLK----NRDFVNLRSW- 117
                         90       100
                 ....*....|....*....|....*..
gi 186526663 348 RGQDGTYTILQFPAVHKKRPAKSGYRR 374
Cdd:cd08871  118 LEFGGEYIIFNHSVKHKKYPPRKGFVR 144
EDR2_C pfam07059
Protein ENHANCED DISEASE RESISTANCE 2, C-terminal; This family represents the C-terminus ...
563-586 2.25e-04

Protein ENHANCED DISEASE RESISTANCE 2, C-terminal; This family represents the C-terminus (approximately 250 residues) of protein ENHANCED DISEASE RESISTANCE 2 (EDR2) from plants. EDR2 is a negative regulator of the salicylic acid (SA)-mediated resistance to pathogens, including the biotrophic powdery mildew pathogens Golovinomyces cichoracearum and Blumeria graminis, and the downy mildew pathogen Hyaloperonospora parasitica, probably by limiting the initiation of cell death and the establishment of the hypersensitive response (HR).


Pssm-ID: 462076  Cd Length: 211  Bit Score: 42.59  E-value: 2.25e-04
                          10        20
                  ....*....|....*....|....
gi 186526663  563 WNSPSGMGFMIRGKTYLKDNAKVA 586
Cdd:pfam07059   1 WSEPDGSTFKVRGPNYLKDKKKVP 24
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH